![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
MASS BALANCE, METABOLIC PROFILE, AND THE ROLE OF HEPATIC AND BACTERIAL ENZYMES IN THE METABOLISM OF THE HCV POLYMERASE INHIBITOR, DELEOBUVIR
|
|
|
Reported by Jules Levin
AASLD 2013 Nov 1-4 Wash DC
R Sane1, L-Z Chen1, E Philip1, S Regan1, H Maw1, H Yu1, A Mathur1, Y Li1, DA Mandarino2, JP Sabo11Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 2Covance Clinical Research Unit Inc., Madison, WI, USA
Rucha Sane rucha.sane@boehringer-ingelheim.com
![AASLD1.gif](../images/110813/111113-8/AASLD1.gif)
![AASLD2.gif](../images/110813/111113-8/AASLD2.gif)
![AASLD3.gif](../images/110813/111113-8/AASLD3.gif)
![AASLD4.gif](../images/110813/111113-8/AASLD4.gif)
![AASLD5.gif](../images/110813/111113-8/AASLD5.gif)
![AASLD6.gif](../images/110813/111113-8/AASLD6.gif)
![AASLD7.gif](../images/110813/111113-8/AASLD7.gif)
![AASLD8.gif](../images/110813/111113-8/AASLD8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|